References

endoserg

Эндокринная хирургия

Endocrine Surgery

2306-35132310-3965

Типография «Печатных дел Мастер»

10.14341/serg12790

endoserg-12790

Research Article

Национальные клинические рекомендации

National clinical recomendations

Проект клинических рекомендаций по диагностике и лечению первичного гиперпаратиреоза у взрослых пациентов

Draft of clinical guidelines for the diagnosis and treatment of primary hyperparathyroidism in adult patients

https://orcid.org/0000-0002-8175-7886

Дедов

И. И.

Dedov

I. I.

Дедов Иван Иванович, д.м.н., академик РАН

Москва

Ivan I. Dedov, MD, PhD, acad.

Moscow

Endocrinesurgery@endocrincentr.ru

https://orcid.org/0000-0002-5634-7877

Мельниченко

Г. А.

Melnichenko

G. A.

Мельниченко Галина Афанасьевна, д.м.н., профессор, академик РАН

Москва

Galina A. Melnichenko, MD, PhD, Prof, acad.

Moscow

https://orcid.org/0000-0002-9717-9742

Мокрышева

Н. Г.

Mokrysheva

N. G.

Мокрышева Наталья Георгиевна, д.м.н., профессор, член-корреспондент РАН

Москва

Natalia G. Mokrysheva, MD, PhD, Professor

Moscow

https://orcid.org/0000-0001-8425-0020

Андреева

Е. Н.

Andreeva

E. N.

Андреева Елена Николаевна, д.м.н., профессор

Москва

Elena N. Andreeva, MD, PhD, professor

Moscow

https://orcid.org/0000-0002-9944-2997

Анциферов

М. Б.

Antsiferov

M. B.

Анциферов Михаил Борисович, д.м.н., профессор

Москва

Mikhail B. Antsiferov, MD, PhD, Professor

Moscow

https://orcid.org/0000-0001-7098-4584

Бельцевич

Д. Г.

Beltsevich

D. G.

Бельцевич Дмитрий Германович, д.м.н., профессор

Москва

Dmitry G. Beltsevich, MD, PhD, Prof.

Moscow

Бибик

Е. Е.

Bibik

E. E.

Бибик Екатерина Евгеньевна

ул. Дмитрия Ульянова, д. 11, 117292 Москва

Ekaterina E. Bibik, MD

11 Dm. Ulyanova street, 117292 Moscow

https://orcid.org/0000-0001-6581-4521

Горбачева

А. М.

Gorbacheva

A. M.

Горбачева Анна Максимовна

ул. Дмитрия Ульянова, д. 11, 117292 Москва

Anna M. Gorbacheva, MD

Moscow

bibikaterina@mail.ru

https://orcid.org/0000-0001-5652-2607

Дегтярев

М. В.

Degtyarev

M. V.

Дегтярев Михаил Владимирович

Москва

Mikhail V. Degtyarev, MD

Moscow

https://orcid.org/0000-0001-8817-1901

Егшатян

Л. В.

Yeghshatyan

L. V.

Егшатян Лилит Ваниковна, к.м.н.

Москва

Lilit V. Egshatyan, MD, PhD

Moscow

https://orcid.org/0000-0001-6667-062X

Еремкина

А. К.

Eremkina

A. K.

Еремкина Анна Константиновна, к.м.н.

Москва

Anna K. Eremkina, MD, PhD

Moscow

https://orcid.org/0000-0002-1547-0123

Каронова

Т. Л.

Karonova

T. L.

Каронова Татьяна Леонидовна, д.м.н.

Санкт-Петербург

Tatiana L. Karonova, MD, PhD

Saint-Petersburg

https://orcid.org/0000-0001-7552-259X

Ким

И. В.

Kim

I. V.

Ким Илья Викторович, к.м.н.

ул. Дмитрия Ульянова, д. 11, 117292 Москва

Ilya V. Kim

11 Dm. Ulyanova street, 117292 Moscow

ilyakim@yandex.ru

https://orcid.org/0000-0001-7963-5022

Крупинова

Ю. А.

Krupinova

J. A.

Крупинова Юлия Александровна

Москва

Julia A. Krupinova, MD

Moscow

https://orcid.org/0000-0002-7876-5105

Крюкова

И. В.

Kryukova

I. V.

Крюкова Ирина Викторовна к.м.н.

Москва

Irina V. Kryukova, MD, PhD

Moscow

https://orcid.org/0000-0002-9419-7013

Кузнецов

Н. С.

Kuznetsov

N. S.

Кузнецов Николай Сергеевич, д.м.н., профессор

Москва

Nikolay S. Kuznetzov, MD, PhD, Professor

Moscow

https://orcid.org/0000-0002-3317-0108

Лукьянов

С. В.

Lukyanov

S. V.

Лукьянов Станислав Викторович, к.м.н.

Ростов-на-Дону

Stanislav V.Lukyanov, MD

Rostov-on-Don

https://orcid.org/0000-0002-9783-3599

Мамедова

Е. О.

Mamedova

E. O.

Мамедова Елизавета Октаевна, к.м.н.

Москва

Elizaveta O. Mamedova, MD, PhD

Moscow

https://orcid.org/0000-0003-2784-1726

Маркина

Н. В.

Markina

N. V.

Маркина Наталья Викторовна к.м.н.

Москва

Natalia V.Markina, MD, PhD, Professor

Moscow

https://orcid.org/0000-0002-1341-0397

Мирная

С. С.

Mirnaya

S. S.

Мирная Светлана Сергеевна, к.м.н.

Москва

Svetlana S. Mirnaya, MD, PhD

Moscow

https://orcid.org/0000-0001-6539-466X

Пигарова

Е. А.

Pigarova

E. A.

Пигарова Екатерина Александровна д.м.н.

Москва

Ekaterina A. Pigarova, MD, PhD

Moscow

https://orcid.org/0000-0001-7041-0732

Рожинская

Л. Я.

Rozhinskaya

L. Ya.

Рожинская Людмила Яковлевна, д.м.н., профессор

Москва

Liudmila Ya. Rozhinskaya, MD, PhD, Professor

Moscow

https://orcid.org/0000-0002-3220-2438

Слащук

К. Ю.

Slashchuk

K. Yu.

Слащук Константин Юрьевич, к.м.н.

Москва

Konstantin Yu. Slashchuk, MD, PhD

Moscow

https://orcid.org/0000-0002-1903-5081

Слепцов

И. В.

Sleptsov

I. V.

Слепцов Илья Валерьевич, д.м.н., профессор

Санкт-Петербург

Ilya V. Sleptsov, MD, PhD, Prof

Saint-Petersburg

https://orcid.org/0000-0001-8022-9291

Чагай

Н. Б.

Chagai

N. B.

Чагай Наталья Борисовна д.м.н., профессор

Ставрополь

Natalia B. Chagai, MD, PhD

Stavropol

Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр эндокринологии» Министерства здравоохранения Российской ФедерацииEndocrinology Research Centre

Государственное бюджетное учреждение здравоохранения города Москвы Эндокринологический диспансер Департамента Здравоохранения города МосквыState Budgetary Institution of Healthcare of the City of Moscow Endocrinological Dispensary of the Department of Healthcare of the City of Moscow

Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В.А. Алмазова» Министерства здравоохранения Российской ФедерацииFederal State Budgetary Institution «Almazov National Medical Research Centre» of the Ministry of Health of the Russian Federation

ГБУЗ Московской области «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского»Moscow Regional Research and Clinical Institute

Федеральное государственное бюджетное образовательное учреждение высшего образования «Ростовский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииFederal State Budgetary Educational Institution of Higher Education «Rostov State Medical University» of the Ministry of Healthcare of the Russian Federation

ООО «Сеть семейных медицинских центров №1»Network of family medical centers No. 1

Клиника высоких медицинских технологий им. Н.И. Пирогова Санкт-Петербургского государственного университетаN.I. Pirogov Clinic of High Medical Technologies of St. Petersburg State University

Федеральное государственное бюджетное образовательное учреждение высшего образования «Ставропольский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииStavropol State Medical University

2022

07042023

164554

Copyright © Дедов И.И., Мельниченко Г.А., Мокрышева Н.Г., Андреева Е.Н., Анциферов М.Б., Бельцевич Д.Г., Бибик Е.Е., Горбачева А.М., Дегтярев М.В., Егшатян Л.В., Еремкина А.К., Каронова Т.Л., Ким И.В., Крупинова Ю.А., Крюкова И.В., Кузнецов Н.С., Лукьянов С.В., Мамедова Е.О., Маркина Н.В., Мирная С.С., Пигарова Е.А., Рожинская Л.Я., Слащук К.Ю., Слепцов И.В., Чагай Н.Б., 2023

2023

Дедов И.И., Мельниченко Г.А., Мокрышева Н.Г., Андреева Е.Н., Анциферов М.Б., Бельцевич Д.Г., Бибик Е.Е., Горбачева А.М., Дегтярев М.В., Егшатян Л.В., Еремкина А.К., Каронова Т.Л., Ким И.В., Крупинова Ю.А., Крюкова И.В., Кузнецов Н.С., Лукьянов С.В., Мамедова Е.О., Маркина Н.В., Мирная С.С., Пигарова Е.А., Рожинская Л.Я., Слащук К.Ю., Слепцов И.В., Чагай Н.Б.

Dedov I.I., Melnichenko G.A., Mokrysheva N.G., Andreeva E.N., Antsiferov M.B., Beltsevich D.G., Bibik E.E., Gorbacheva A.M., Degtyarev M.V., Yeghshatyan L.V., Eremkina A.K., Karonova T.L., Kim I.V., Krupinova J.A., Kryukova I.V., Kuznetsov N.S., Lukyanov S.V., Mamedova E.O., Markina N.V., Mirnaya S.S., Pigarova E.A., Rozhinskaya L.Y., Slashchuk K.Y., Sleptsov I.V., Chagai N.B.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.surg-endojournals.ru/jour/article/view/12790

В статье представлен проект клинических рекомендаций по диагностике и лечению первичного гиперпаратиреоза у взрослых пациентов, в котором приведен современный алгоритм обследования, рассмотрены основные принципы лабораторной, инструментальной диагностики и подходы к лечению.

The article presents a draft of clinical recommendations for the diagnosis and treatment of primary hyperparathyroidism in adult patients, which provides a modern examination algorithm, discusses the basic principles of laboratory, instrumental diagnostics and treatment approaches.

Околощитовидные железыпервичный гиперпаратиреозклинические рекомендации

parathyroid glandsprimary hyperparathyroidismguidelines

References1

Мокрышева, Н., и др., Анализ основных эпидемиологических характеристик первичного гиперпаратиреоза в России (по данным регистра). Проблемы эндокринологии, 2012. 58(5).

Bilezikian, J.P., et al., Primary hyperparathyroidism. Nature reviews Disease primers, 2016. 2: p. 16033.

Walker, M.D. and J.P. Bilezikian, Vitamin D and primary hyperparathyroidism: more insights into a complex relationship. 2017, Springer.

Cromer, M.K., et al., Identification of somatic mutations in parathyroid tumors using whole-exome sequencing. The Journal of Clinical Endocrinology & Metabolism, 2012. 97(9): p. E1774-E1781.

Thakker, R., Genetics of parathyroid tumours. Journal of internal medicine, 2016. 280(6): p. 574-583.

Bricaire, L., et al., Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 2013. 98(2): p. E403-E408.

Warner, J., et al., Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. Journal of Medical Genetics, 2004. 41(3): p. 155-160.

Yu, W., et al., Whole-exome sequencing studies of parathyroid carcinomas reveal novel PRUNE2 mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with cell migration and invasion. The Journal of Clinical Endocrinology & Metabolism, 2015. 100(2): p. E360-E364.

Wermers, R.A., et al., The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Annals of Internal Medicine, 1997. 126(6): p. 433-440.

Khan, A.A., et al., Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int, 2017. 28(1): p. 1-19.

Clarke, B.L., Asymptomatic Primary Hyperparathyroidism, in Parathyroid Disorders. 2019, Karger Publishers. p. 13-22.

Christensson, T., et al., Prevalence of hypercalcaemia in a health screening in Stockholm. Acta Medica Scandinavica, 1976. 200(1‐6): p. 131-137.

Palmer, M., et al., Prevalence of hypercalcaemia in a health survey: a 14‐year follow‐up study of serum calcium values. European journal of clinical investigation, 1988. 18(1): p. 39-46.

Yu, N., et al., Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clinical endocrinology, 2009. 71(4): p. 485-493.

Siilin, H., et al., Prevalence of primary hyperparathyroidism and impact on bone mineral density in elderly men: MrOs Sweden. World journal of surgery, 2011. 35(6): p. 1266-1272.

Yeh, M.W., et al., Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. The Journal of Clinical Endocrinology & Metabolism, 2013. 98(3): p. 1122-1129.

Cusano, N.E., et al., Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. The Journal of Clinical Endocrinology & Metabolism, 2013. 98(7): p. 2734-2741.

Rubin, M.R., et al., The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. The Journal of Clinical Endocrinology & Metabolism, 2008. 93(9): p. 3462-3470.

Silverberg, S.J., et al., A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. New England Journal of Medicine, 1999. 341(17): p. 1249-1255.

Vestergaard, P., et al., Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg, 2003. 27(2): p. 216-22.

Вороненко, И., и др., Состояние сердечно-сосудистой системы при клинически выраженном и малосимптомном первичном гиперпаратиреозе. Проблемы эндокринологии, 2009. 3: p. 17-22.

Vestergaard, P. and L. Mosekilde, Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ, 2003. 327(7414): p. 530-4.

Thomas, A. and A. Kautzky-Willer, Diabetes in hyperparathyroidism, in Diabetes Secondary to Endocrine and Pancreatic Disorders. 2014, Karger Publishers. p. 92-100.

Procopio, M., et al., Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. Endocrine, 2014. 47(2): p. 581-9.

Mendoza-Zubieta, V., et al., High prevalence of metabolic syndrome in a mestizo group of adult patients with primary hyperparathyroidism (PHPT). BMC Endocrine Disorders, 2015. 15(1): p. 16.

Christensen, S.E., et al., Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow‐up study on methods. Clinical endocrinology, 2008. 69(5): p. 713-720.

Nordenström, E., P. Katzman, and A. Bergenfelz, Biochemical diagnosis of primary hyperparathyroidism: analysis of the sensitivity of total and ionized calcium in combination with PTH. Clinical biochemistry, 2011. 44(10-11): p. 849-852.

Amin, A.L., et al., Normal PTH levels in primary hyperparathyroidism: still the same disease? Annals of surgical oncology, 2011. 18(12): p. 3437-3442.

Monchik, J.M. and E. Gorgun, Normocalcemic hyperparathyroidism in patients with osteoporosis. Surgery, 2004. 136(6): p. 1242-1246.

Lowe, H., et al., Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. The Journal of Clinical Endocrinology & Metabolism, 2007. 92(8): p. 3001-3005.

Silverberg, S.J. and J.P. Bilezikian, “Incipient” primary hyperparathyroidism: a “forme fruste” of an old disease. The Journal of Clinical Endocrinology & Metabolism, 2003. 88(11): p. 5348-5352.

Maeda, S.S., et al., Factors affecting vitamin D status in different populations in the city of São Paulo, Brazil: the São PAulo vitamin D Evaluation Study (SPADES). BMC endocrine disorders, 2013. 13(1): p. 14.

Ross, A.C., et al., The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. The Journal of Clinical Endocrinology & Metabolism, 2011. 96(1): p. 53-58.

Martinez, I., et al., The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. American journal of kidney diseases, 1997. 29(4): p. 496-502.

Walker, M.D., et al., Effect of renal function on skeletal health in primary hyperparathyroidism. J Clin Endocrinol Metab, 2012. 97(5): p. 1501-7.

Coe, F.L., et al., Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. The Journal of clinical investigation, 1973. 52(1): p. 134-142.

Balsa, J., et al., Role of calcium malabsorption in the development of secondary hyperparathyroidism after biliopancreatic diversion. Journal of endocrinological investigation, 2008. 31(10): p. 845-850.

Selby, P.L., et al., Bone loss in celiac disease is related to secondary hyperparathyroidism. Journal of Bone and Mineral Research, 1999. 14(4): p. 652-657.

Rejnmark, L., et al., Effects of thiazide‐and loop‐diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study. Journal of internal medicine, 2001. 250(2): p. 144-153.

MALLETTE, L.E., et al., Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume. The Journal of Clinical Endocrinology & Metabolism, 1989. 68(3): p. 654-660.

Makras, P., et al., Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Clinical endocrinology, 2013. 79(4): p. 499-503.

Fraser, W.D., et al., Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget’s disease of bone and hypercalcaemia of malignancy. Bone and mineral, 1991. 12(2): p. 113-121.

Udén, P., et al., Primary hyperparathyroidism in younger and older patients: symptoms and outcome of surgery. World journal of surgery, 1992. 16(4): p. 791-797.

Reid, L., et al., Presentation, diagnostic assessment and surgical outcomes in primary hyperparathyroidism: a single centre’s experience. Endocrine connections, 2018. 1(aop).

Di Monaco, M., et al., Primary hyperparathyroidism in elderly patients with hip fracture. Journal of bone and mineral metabolism, 2004. 22(5): p. 491-495.

Bergström, I., B.-M. Landgren, and B. Freyschuss, Primary hyperparathyroidism is common in postmenopausal women with forearm fracture and low bone mineral density. Acta obstetricia et gynecologica Scandinavica, 2007. 86(1): p. 61-64.

Bandeira, F., et al., From mild to severe primary hyperparathyroidism: the Brazilian experience. Arquivos Brasileiros de Endocrinologia & Metabologia, 2006. 50(4): p. 657-663.

Khosla, S., et al., Primary hyperparathyroidism and the risk of fracture: a population‐based study. Journal of Bone and Mineral Research, 1999. 14(10): p. 1700-1707.

Yadav, S.K., et al., Primary hyperparathyroidism in developing world: a systematic review on the changing clinical profile of the disease. Archives of Endocrinology and Metabolism, 2020. 64(2): p. 105-110.

Wikström, B., et al., Ambulatory diagnostic evaluation of 389 recurrent renal stone formers. Klinische Wochenschrift, 1983. 61(2): p. 85-90.

Fuss, M., et al., Infrequency of primary hyperparathyroidism in renal stone formers. British journal of urology, 1988. 62(1): p. 4-6.

Walker, V., E.M. Stansbridge, and D.G. Griffin, Demography and biochemistry of 2800 patients from a renal stones clinic. Annals of clinical biochemistry, 2013. 50(2): p. 127-139.

Sharma, S., et al., PREVALENCE AND PREDICTORS OF PRIMARY HYPERPARATHYROIDISM AMONG PATIENTS WITH UROLITHIASIS. Endocrine Practice, 2017. 23(11): p. 1311-1315.

Kim, J.-k., et al., The prevalence of primary hyperparathyroidism in Korea: a population-based analysis from patient medical records. Annals of surgical treatment and research, 2018. 94(5): p. 235-239. 55. Sorensen, M.D., et al., Urinary parameters as predictors of primary hyperparathyroidism in patients with nephrolithiasis. The Journal of urology, 2012. 187(2): p. 516-521.

Ebert, E.C., The parathyroids and the gut. Journal of clinical gastroenterology, 2010. 44(7): p. 479-482.

Gasparoni, P., et al., Primary hyperparathyroidism and peptic ulcer. Minerva medica, 1989. 80(12): p. 1327-1330.

Jacob, J.J., et al., Does hyperparathyroidism cause pancreatitis? A South Indian experience and a review of published work. ANZ journal of surgery, 2006. 76(8): p. 740-744.

Inzucchi, S.E., Understanding hypercalcemia: its metabolic basis, signs, and symptoms. Postgraduate medicine, 2004. 115(4): p. 69-76.

Walsh, J., N. Gittoes, and P. Selby, SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Emergency management of acute hypercalcaemia in adult patients. Endocrine connections, 2016. 5(5): p. G9-G11.

Suh, J.M., J.J. Cronan, and J.M. Monchik, Primary hyperparathyroidism: is there an increased prevalence of renal stone disease? American Journal of Roentgenology, 2008. 191(3): p. 908-911.

Cipriani, C., et al., Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology. The Journal of Clinical Endocrinology & Metabolism, 2015. 100(4): p. 1309-1315.

Miller, P.D. and J.P. Bilezikian, Bone densitometry in asymptomatic primary hyperparathyroidism. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research, 2002. 17: p. N98.

Abboud, B., R. Daher, and J. Boujaoude, Digestive manifestations of parathyroid disorders. World Journal of Gastroenterology: WJG, 2011. 17(36): p. 4063.

FRAME, B. and W.S. HAUBRICH, Peptic ulcer and hyperparathyroidism: a survey of 300 ulcer patients. AMA Archives of Internal Medicine, 1960. 105(4): p. 536-541.

Corleto, V., et al., Prevalence and causes of hypergastrinemia in primary hyperparathyroidism: a prospective study. The Journal of Clinical Endocrinology & Metabolism, 1999. 84(12): p. 4554-4558.

Norton, J.A., et al., Prospective study of surgery for primary Hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 (MEN1), and Zollinger-Ellison syndrome (ZES): long-term outcome of a more virulent form of HPT. Annals of surgery, 2008. 247(3): p. 501.

Turken, S.A., et al., Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. The American journal of medicine, 1989. 87(5): p. 553-557.

Coker, L.H., et al., Primary hyperparathyroidism, cognition, and healthrelated quality of life. Annals of surgery, 2005. 242(5): p. 642.

Morris, G.S., et al., Parathyroidectomy improves functional capacity in “asymptomatic” older patients with primary hyperparathyroidism: a randomized control trial. Annals of surgery, 2010. 251(5): p. 832-837.

Walker, M.D., et al., Neuropsychological features in primary hyperparathyroidism: a prospective study. J Clin Endocrinol Metab, 2009. 94(6): p. 1951-8.

Murray, S.E., et al., Improvement of sleep disturbance and insomnia following parathyroidectomy for primary hyperparathyroidism. World journal of surgery, 2014. 38(3): p. 542-548.

Blanchard, C., et al., Surgery for ‘asymptomatic’mild primary hyperparathyroidism improves some clinical symptoms postoperatively. European Journal of Endocrinology, 2013. 169(5): p. 665-672.

Bilezikian, J.P., et al., Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop, in J Clin Endocrinol Metab. 2014. p. 3561-9.

Ong, G.S., et al., The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 2012. 97(9): p. 3138-3145.

Thode, J., et al., Comparison of serum total calcium, albumincorrected total calcium, and ionized calcium in 1213 patients with suspected calcium disorders. Scandinavian journal of clinical and laboratory investigation, 1989. 49(3): p. 217-223.

Gao, P. and P. D’Amour, Evolution of the parathyroid hormone (PTH) assay--importance of circulating PTH immunoheterogeneity and of its regulation. Clinical laboratory, 2005. 51(1-2): p. 21-29.

Boudou, P., et al., Third-or second-generation parathyroid hormone assays: a remaining debate in the diagnosis of primary hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 2005. 90(12): p. 6370-6372.

Hedbäck, G. and A. Oden, Cardiovascular disease, hypertension and renal function in primary hyperparathyroidism. Journal of internal medicine, 2002. 251(6): p. 476-483.

Benson, L., et al., Optimal discrimination of mild hyperparathyroidism with total serum calcium, ionized calcium and parathyroid hormone measurements. Upsala Journal of Medical Sciences, 1987. 92(2): p. 147-176.

Forster, J., J. Monchik, and H.F. Martin, A comparative study of serum ultrafiltrable, ionized, and total calcium in the diagnosis of primary hyperparathyroidism in patients with intermittent or no elevation in total calcium. Surgery, 1988. 104(6): p. 1137-1142.

Rubin, M.R., et al., An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH (1–84) is overproduced in parathyroid carcinoma. Clinical chemistry, 2007. 53(8): p. 1470-1476.

Yamashita, H., et al., Influence of renal function on clinicopathological features of primary hyperparathyroidism. European journal of endocrinology, 2003. 148(6): p. 597-602.

Wang, W.-H., et al., Association between parathyroid hormone, 25 (OH) vitamin D, and chronic kidney disease: a population-based study. BioMed Research International, 2017. 2017.

Tassone, F., et al., Glomerular filtration rate and parathyroid hormone secretion in primary hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 2009. 94(11): p. 4458-4461.

Muthukrishnan, J., et al., Distal renal tubular acidosis due to primary hyperparathyroidism. Endocrine Practice, 2008. 14(9): p. 1133-1136.

Bilezikian, J.P., et al., Primary hyperparathyroidism in women: a tale of two cities--New York and Beijing. International journal of fertility and women’s medicine, 2000. 45(2): p. 158-165.

Bandeira, F., et al., Relationship between serum vitamin D status and clinical manifestations of primary hyperparathyroidism. Endocrine Practice, 2002. 8(4): p. 266-270.

Moosgaard, B., et al., Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clinical endocrinology, 2005. 63(5): p. 506-513.

Bilezikian, J.P. and S.J. Silverberg, Normocalcemic primary hyperparathyroidism. Arquivos Brasileiros de Endocrinologia & Metabologia, 2010. 54(2): p. 106-109.

Hannan, F.M., et al., Identification of 70 calcium-sensing receptor mutations in hyper- and hypo-calcaemic patients: evidence for clustering of extracellular domain mutations at calcium-binding sites. Human Molecular Genetics, 2012. 21(12): p. 2768-2778.

Dershem, R., et al., Familial Hypocalciuric Hypercalcemia Type 1 and Autosomal-Dominant Hypocalcemia Type 1: Prevalence in a Large Healthcare Population. The American Journal of Human Genetics, 2020. 106(6): p. 734-747.

Eisner, B.H., J. Ahn, and M.L. Stoller, Differentiating primary from secondary hyperparathyroidism in stone patients: the “thiazide challenge”. Journal of endourology, 2009. 23(2): p. 191-192.

Пампутис, С. и Е. Лопатникова, ДИФФЕРЕНЦИАЛЬНАЯ ДИАГНОСТИКА НОРМОКАЛЬЦИЕМИЧЕСКОГО ПЕРВИЧНОГО ГИПЕРПАРАТИРЕОЗА С ИСПОЛЬЗОВАНИЕМ ДИАГНОСТИЧЕСКОГО ТЕСТА» ПРОБА С АЛЬФАКАЛЬЦИДОЛОМ». Таврический медикобиологический вестник, 2017. 20(3-2).

Valcour, A., et al., Effects of age and serum 25-OH-vitamin D on serum parathyroid hormone levels. The Journal of Clinical Endocrinology & Metabolism, 2012. 97(11): p. 3989-3995.

Björkman, M., A. Sorva, and R. Tilvis, Responses of parathyroid hormone to vitamin D supplementation: a systematic review of clinical trials. Archives of gerontology and geriatrics, 2009. 48(2): p. 160-166.

Eisner, B.H., J. Ahn, and M.L. Stoller, Differentiating primary from secondary hyperparathyroidism in stone patients: the «thiazide challenge». J Endourol, 2009. 23(2): p. 191-2.

Saliba, W., et al., The relationship between serum 25 (OH) D and parathyroid hormone levels. The American journal of medicine, 2011. 124(12): p. 1165-1170.

Holick, M.F., Vitamin D deficiency. New England Journal of Medicine, 2007. 357(3): p. 266-281.

Parfitt, A., The interactions of thiazide diuretics with parathyroid hormone and vitamin D: Studies in patients with hypoparathyroidism. The Journal of clinical investigation, 1972. 51(7): p. 1879-1888.

100

Holick, M.F., et al., Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 2011. 96(7): p. 1911-1930 %@ 0021-972X.

101

Levin, A., et al., Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney International, 2007. 71(1): p. 31-38.

102

Пигарова, Е.А., et al., Клинические рекомендации Российской ассоциации эндокринологов по диагностике, лечению и профилактике дефицита витамина D у взрослых. Проблемы эндокринологии, 2016. 62(4).

103

Дедов, И.И., et al., Первичный гиперпаратиреоз: клиника, диагностика, дифференциальная диагностика, методы лечения. Проблемы эндокринологии, 2016. 62(6).

104

Карасева, Е.В., и др., Возможности применения короткой функциональной пробы с активными метаболитами витамина D в дифференциальной диагностике первичного и вторичного гиперпаратиреоза в условиях стационара. Профилактическая медицина, 2022. 25(6): p. 68-74.

105

Еремкина, А.К., и др., Возможности применения короткой функциональной пробы с гидрохлоротиазидом в дифференциальной диагностике первичного и вторичного гиперпаратиреоза в условиях стационара. Проблемы эндокринологии, 2022. 4(68).

106

Cheung, K., et al., A meta-analysis of preoperative localization techniques for patients with primary hyperparathyroidism. Annals of surgical oncology, 2012. 19(2): p. 577-583.

107

Moghadam, R.N., et al., Comparative diagnostic performance of ultrasonography and 99mTc-sestamibi scintigraphy for parathyroid adenoma in primary hyperparathyroidism; systematic review and meta-analysis. Asian Pacific journal of cancer prevention: APJCP, 2017. 18(12): p. 3195.

108

Ruda, J.M., C.S. Hollenbeak, and B.C. Stack Jr, A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngology—Head and Neck Surgery, 2005. 132(3): p. 359-372.

109

Артемова, А., Сравнительная оценка методов топической диагностики при первичном гиперпаратиреозе. Тезисы докладов Международного научного форума «Патология паращитовидных желез: современные подходы к диагностике и лечению». — Санкт-Петербург, 2010: p. 29-30.

110

Untch, B.R., et al., Surgeon-performed ultrasound is superior to 99Tcsestamibi scanning to localize parathyroid adenomas in patients with primary hyperparathyroidism: results in 516 patients over 10 years. Journal of the American College of Surgeons, 2011. 212(4): p. 522-529.

111

Carlier, T., et al., 99m Tc-MIBI pinhole SPECT in primary hyperparathyroidism: comparison with conventional SPECT, planar scintigraphy and ultrasonography. European journal of nuclear medicine and molecular imaging, 2008. 35(3): p. 637-643.

112

Witteveen, J., et al., Therapy of endocrine disease: hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. European Journal of Endocrinology, 2013. 168(3): p. R45-R53.

113

Nam, M., H.-S. Jeong, and J.H. Shin, Differentiation of parathyroid carcinoma and adenoma by preoperative ultrasonography. Acta Radiologica, 2017. 58(6): p. 670-675.

114

Agha, A., et al., The role of contrast-enhancend ultrasonography (CEUS) in comparison with 99mTechnetium-sestamibi scintigraphy for localization diagnostic of primary hyperparathyroidism. Clinical hemorheology and microcirculation, 2014. 58(4): p. 515-520.

115

Kluijfhout, W.P., et al., Use of PET tracers for parathyroid localization: a systematic review and meta-analysis. Langenbecks Arch Surg, 2016. 401(7): p. 925-935.

116

Leslie, W.D., et al., Parathyroid 99m Tc-sestamibi scintigraphy: dualtracer subtraction is superior to double-phase washout. European journal of nuclear medicine and molecular imaging, 2002. 29(12): p. 1566-1570.

117

Kluijfhout, W.P., et al., Diagnostic performance of computed tomography for parathyroid adenoma localization; a systematic review and meta-analysis. European journal of radiology, 2017. 88: p. 117-128.

118

Паша, С.П., Клиническая значимость радионуклидных методов визуализации паращитовидных желез при гиперпаратиреозе. Russian Electronic Journal Of Radiology, 2015. 5: p. 11-21.

119

Hindié, E., et al., 2009 EANM parathyroid guidelines. Eur J Nucl Med Mol Imaging, 2009. 36(7): p. 1201-16.

120

Maccora, D., et al., Parathyroid scintigraphy in primary hyperparathyroidism: comparison between double-phase and subtraction techniques and possible affecting factors. J Endocrinol Invest, 2019. 42(8): p. 889-895.

121

Taieb, D., et al., Parathyroid scintigraphy: when, how, and why? A concise systematic review. Clin Nucl Med, 2012. 37(6): p. 568-74.

122

Neumann, D.R., N.A. Obuchowski, and F.P. Difilippo, Preoperative 123I/99mTc-sestamibi subtraction SPECT and SPECT/CT in primary hyperparathyroidism. J Nucl Med, 2008. 49(12): p. 2012-7.

123

Wong, K.K., et al., Parathyroid adenoma localization with 99mTcsestamibi SPECT/CT: a meta-analysis. Nucl Med Commun, 2015. 36(4): p. 363-75.

124

Singer, M.C., et al., Improved localization of sestamibi imaging at high-volume centers. Laryngoscope, 2013. 123(1): p. 298-301.

125

Ciappuccini, R., et al., Dual-phase 99mTc sestamibi scintigraphy with neck and thorax SPECT/CT in primary hyperparathyroidism: a singleinstitution experience. Clin Nucl Med, 2012. 37(3): p. 223-8.

126

Zhou, J., et al., Diagnosis performance of (99m)Tc-MIBI and multimodality imaging for hyperparathyroidism. J Huazhong Univ Sci Technolog Med Sci, 2017. 37(4): p. 582-586.

127

Слащук, К.Ю., и др., Предоперационная визуализация и интраоперационная навигация новообразований околощитовидных желез при первичном гиперпаратиреозе. Опухоли головы и шеи, 2021. 11(4): p. 10-21.

128

Okudan, B., et al., Comparison between single-photon emission computed tomography/computed tomography and ultrasound in preoperative detection of parathyroid adenoma: retrospective review of an institutional experience. Nuclear medicine communications, 2019. 40(12): p. 1211-1215.

129

Casara, D., et al., 99m Tc-MIBI radio-guided minimally invasive parathyroid surgery planned on the basis of a preoperative combined 99m Tc-pertechnetate/99m Tc-MIBI and ultrasound imaging protocol. European journal of nuclear medicine, 2000. 27(9): p. 1300-1304.

130

Wakamatsu, H., et al., Parathyroid scintigraphy with 99mTc-MIBI and 123I subtraction: a comparison with magnetic resonance imaging and ultrasonography. Nuclear medicine communications, 2003. 24(7): p. 755-762.

131

Kluijfhout, W.P., et al., Use of PET tracers for parathyroid localization: a systematic review and meta-analysis. Langenbeck’s archives of surgery, 2016. 401(7): p. 925-935.

132

Ruf, J., et al., Preoperative localization of parathyroid glands. Nuklearmedizin, 2004. 43(03): p. 85-90.

133

Hunter, G.J., et al., Accuracy of four-dimensional CT for the localization of abnormal parathyroid glands in patients with primary hyperparathyroidism. (1527-1315 (Electronic)).

134

Lubitz, C.C., et al., Accuracy of 4-dimensional computed tomography in poorly localized patients with primary hyperparathyroidism. Surgery, 2010. 148(6): p. 1129-37; discussion 1137-8.

135

Starker, L.F., et al., 4D parathyroid CT as the initial localization study for patients with de novo primary hyperparathyroidism. Ann Surg Oncol, 2011. 18(6): p. 1723-8.

136

Harari, A., et al., Computed tomography can guide focused exploration in select patients with primary hyperparathyroidism and negative sestamibi scanning. Surgery, 2008. 144(6): p. 970-6; discussion 976-9.

137

Beggs, A.D. and S.F. Hain, Localization of parathyroid adenomas using 11C-methionine positron emission tomography. Nucl Med Commun, 2005. 26(2): p. 133-6.

138

Treglia, G., et al., Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging, 2019. 46(3): p. 751-765.

139

Erbil, Y., et al., Value of parathyroid hormone assay for preoperative sonographically guided parathyroid aspirates for minimally invasive parathyroidectomy. Journal of Clinical Ultrasound, 2006. 34(9): p. 425-429.

140

Barczynski, M., et al., Technetium‐99m‐sestamibi subtraction scintigraphy vs. ultrasonography combined with a rapid parathyroid hormone assay in parathyroid aspirates in preoperative localization of parathyroid adenomas and in directing surgical approach. Clinical endocrinology, 2006. 65(1): p. 106-113.

141

Giusti, M., et al., Institutional experience of PTH evaluation on fineneedle washing after aspiration biopsy to locate hyperfunctioning parathyroid tissue. Journal of Zhejiang University SCIENCE B, 2009. 10(5): p. 323-330.

142

Ким, И., Н. Кузнецов, и С. Кузнецов, Исследование паратгормона из смыва при пункционной биопсии околощитовидных желез как метод топической диагностики при первичном гиперпаратиреозе. Эндокринная хирургия, 2014(2).

143

Marshall, D., O. Johnell, and H. Wedel, Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Bmj, 1996. 312(7041): p. 1254-1259.

144

Marcocci, C., L. Cianferotti, and F. Cetani, Bone disease in primary hyperparathyrodism. Therapeutic advances in musculoskeletal disease, 2012. 4(5): p. 357-368.

145

Wood, K., et al., What is the utility of distal forearm DXA in primary hyperparathyroidism? The oncologist, 2012. 17(3): p. 322.

146

Bandeira, F., et al., Bone disease in primary hyperparathyroidism. Arquivos Brasileiros de Endocrinologia & Metabologia, 2014. 58(5): p. 553-561.

147

Briot, K., et al., Accuracy of patient-reported height loss and risk factors for height loss among postmenopausal women. Cmaj, 2010. 182(6): p. 558-562.

148

Abdelhadi, M. and J.r. Nordenström, Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 1998. 83(11): p. 3845-3851.

149

PARISIEN, M., et al., The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. The Journal of Clinical Endocrinology & Metabolism, 1990. 70(4): p. 930-938.

150

Hansen, S., et al., Effects on bone geometry, density, and microarchitecture in the distal radius but not the tibia in women with primary hyperparathyroidism: A case‐control study using HR‐pQCT. Journal of Bone and Mineral Research, 2010. 25(9): p. 1941-1947.

151

Stein, E.M., et al., Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. Journal of Bone and Mineral Research, 2013. 28(5): p. 1029-1040.

152

Romagnoli, E., et al., “Trabecular Bone Score”(TBS): an indirect measure of bone micro-architecture in postmenopausal patients with primary hyperparathyroidism. Bone, 2013. 53(1): p. 154-159.

153

Silva, B.C., et al., Trabecular bone score (TBS)—a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 2013. 98(5): p. 1963-1970.

154

Khosla, S., et al., Primary hyperparathyroidism and the risk of fracture: a population‐based study. Journal of Bone and Mineral Research, 1999. 14(10): p. 1700-1707.

155

Vignali, E., et al., Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 2009. 94(7): p. 2306-2312.

156

Kulak, C.A.M., et al., Marked improvement in bone mass after parathyroidectomy in osteitis fibrosa cystica. The Journal of Clinical Endocrinology & Metabolism, 1998. 83(3): p. 732-735.

157

Hansen, S., et al., Parathyroidectomy improves bone geometry and microarchitecture in female patients with primary hyperparathyroidism: A one‐year prospective controlled study using high‐resolution peripheral quantitative computed tomography. Journal of Bone and Mineral Research, 2012. 27(5): p. 1150-1158.

158

Eller-Vainicher, C., et al., Bone quality, as measured by trabecular bone score, in patients with primary hyperparathyroidism. European journal of endocrinology, 2013. 169(2): p. 155-162.

159

Starup-Linde, J., et al., Renal stones and calcifications in patients with primary hyperparathyroidism: associations with biochemical variables. European Journal of Endocrinology, 2012. 166(6): p. 1093-1100.

160

Odvina, C.V., et al., Biochemical characterization of primary hyperparathyroidism with and without kidney stones. Urological research, 2007. 35(3): p. 123-128.

161

Corbetta, S., et al., Risk factors associated to kidney stones in primary hyperparathyroidism. Journal of endocrinological investigation, 2005. 28(4): p. 122-128.

162

Rejnmark, L., P. Vestergaard, and L. Mosekilde, Nephrolithiasis and renal calcifications in primary hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 2011. 96(8): p. 2377-2385.

163

Bouzidi, H., D. de Brauwere, and M. Daudon, Does urinary stone composition and morphology help for prediction of primary hyperparathyroidism? Nephrology Dialysis Transplantation, 2010. 26(2): p. 565-572.

164

Mallette, L., et al., Primary hyperparathyroidism: clinical and biochemical features. Medicine, 1974. 53(2): p. 127-146.

165

Bai, H.X., et al., The association of primary hyperparathyroidism with pancreatitis. Journal of clinical gastroenterology, 2012. 46(8): p. 656.

166

Procopio, M., et al., Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. Endocrine, 2014. 47(2): p. 581-589.

167

Горбачева, А.М., и др., Структура метаболических нарушений и сердечно-сосудистых заболеваний у пациентов с первичным гиперпаратиреозом: одноцентровое ретроспективное обсервационное исследование. Профилактическая медицина, 2022. 25(8): p. 54-66.

168

Бибик, Е.Е., и др., Изменения метаболических параметров у пациентов с первичным гиперпаратиреозом различных возрастных групп. Ожирение и метаболизм, 2022. 19(3).

169

Добрева, Е.А., и др., Кардиоваскулярные нарушения у пациентов с первичным гиперпаратиреозом по данным регистра. Профилактическая медицина, 2020. 23: p. 13-22.

170

Tassone, F., et al., Prevalence and characteristics of metabolic syndrome in primary hyperparathyroidism. J Endocrinol Invest, 2012. 35(9): p. 841-6.

171

Han, D., S. Trooskin, and X. Wang, Prevalence of cardiovascular risk factors in male and female patients with primary hyperparathyroidism. J Endocrinol Invest, 2012. 35(6): p. 548-52.

172

Yavari, M., et al., The influence of parathyroidectomy on cardiometabolic risk factors in patients with primary hyperparathyroidism: a systematic review and meta-analysis. Endocrine, 2021. 72(1): p. 72-85.

173

Walker, M.D. and S.J. Silverberg, Cardiovascular aspects of primary hyperparathyroidism. Journal of Endocrinological Investigation, 2008. 31(10): p. 925-931.

174

Vestergaard, P., et al., Cardiovascular Events before and after Surgery for Primary Hyperparathyroidism. World Journal of Surgery, 2003. 27(2): p. 216-222.

175

Clifton-Bligh, P.B., et al., Mortality associated with primary hyperparathyroidism. Bone, 2015. 74: p. 121-124.

176

Bolland, M.J., et al., Association between Primary Hyperparathyroidism and Increased Body Weight: A Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism, 2005. 90(3): p. 1525-1530.

177

Frey, S., et al., Impact of parathyroidectomy on cardiovascular risk in primary hyperparathyroidism: A narrative review. Nutr Metab Cardiovasc Dis, 2021. 31(4): p. 981-996.

178

Kouvaraki, M.A., et al., Indications for operative intervention in patients with asymptomatic primary hyperparathyroidism: practice patterns of endocrine surgery. Surgery, 2006. 139(4): p. 527-534.

179

Vestergaard, P. and L. Mosekilde, Fractures in patients with primary hyperparathyroidism: nationwide follow-up study of 1201 patients. World J Surg, 2003. 27(3): p. 343-9.

180

Tassone, F., et al., Parathyroidectomy halts the deterioration of renal function in primary hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 2015. 100(8): p. 3069-3073.

181

Rose, D.M., et al., Long-term management and outcome of parathyroidectomy for sporadic primary multiple-gland disease. Archives of Surgery, 2001. 136(6): p. 621-626.

182

Sivula, A. and R. Pelkonen, Long-term health risk of primary hyperparathyroidism: the effect of surgery. Annals of medicine, 1996. 28(2): p. 95-100.

183

Norenstedt, S., et al., Primary hyperparathyroidism and metabolic risk factors; impact of parathyroidectomy and vitamin D supplementation; results of a randomized double-blind study. European journal of endocrinology, 2013: p. EJE-13-0547.

184

Shah, V., et al., Influence of age and gender on presentation of symptomatic primary hyperparathyroidism. Journal of postgraduate medicine, 2012. 58(2): p. 107.

185

Silverberg, S.J., I. Brown, and J.P. Bilezikian, Age as a criterion for surgery in primary hyperparathyroidism. The American journal of medicine, 2002. 113(8): p. 681-681.

186

VanderWalde, L.H., I.-L.A. Liu, and P.I. Haigh, Effect of bone mineral density and parathyroidectomy on fracture risk in primary hyperparathyroidism. World journal of surgery, 2009. 33(3): p. 406-411.

187

Fang, W.L., et al., The management of high‐risk patients with primary hyperparathyroidism–minimally invasive parathyroidectomy vs. medical treatment. Clinical endocrinology, 2008. 68(4): p. 520-528.

188

Rao, D.S., et al., Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 2004. 89(11): p. 5415-5422.

189

Vestergaard, P., et al., Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. Bmj, 2000. 321(7261): p. 598-602.

190

Bollerslev, J., et al., Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. The Journal of Clinical Endocrinology & Metabolism, 2007. 92(5): p. 1687-1692.

191

Roschger, P., et al., New observations on bone quality in mild primary hyperparathyroidism as determined by quantitative backscattered electron imaging. Journal of Bone and Mineral Research, 2007. 22(5): p. 717-723.

192

Ambrogini, E., et al., Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. The Journal of Clinical Endocrinology & Metabolism, 2007. 92(8): p. 3114-3121.

193

Lundstam, K., et al., Effect of Surgery Versus Observation: Skeletal 5‐Year Outcomes in a Randomized Trial of Patients With Primary HPT (the SIPH Study). Journal of Bone and Mineral Research, 2017. 32(9): p. 1907-1914.

194

Vestergaard, P. and L. Mosekilde, Parathyroid surgery is associated with a decreased risk of hip and upper arm fractures in primary hyperparathyroidism: a controlled cohort study. Journal of internal medicine, 2004. 255(1): p. 108-114.

195

Peacock, M., Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research, 2002. 17: p. N87-94.

196

Salahudeen, A., et al., Hypertension and renal dysfunction in primary hyperparathyroidism: effect of parathyroidectomy. Clinical Science, 1989. 76(3): p. 289-296.

197

Mollerup, C.L., et al., Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. Bmj, 2002. 325(7368): p. 807.

198

Deaconson, T.F., S.D. Wilson, and L. Jacob, The effect of parathyroidectomy on the recurrence of nephrolithiasis. Surgery, 1987. 102(6): p. 910-913.

199

Hedbäck, G., K. Abrahamsson, and A. Oden, The improvement of renal concentration capacity after surgery for primary hyperparathyroidism. European journal of clinical investigation, 2001. 31(12): p. 1048-1053.

200

Sejean, K., et al., Surgery versus medical follow-up in patients with asymptomatic primary hyperparathyroidism: a decision analysis. European journal of endocrinology, 2005. 153(6): p. 915-927.

201

Zanocco, K., P. Angelos, and C. Sturgeon, Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. Surgery, 2006. 140(6): p. 874-882.

202

Zanocco, K. and C. Sturgeon, How should age at diagnosis impact treatment strategy in asymptomatic primary hyperparathyroidism? A cost-effectiveness analysis. Surgery, 2008. 144(2): p. 290-298.

203

Wilhelm, S.M., et al., The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA surgery, 2016. 151(10): p. 959-968.

204

Udelsman, R., et al., The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. The Journal of Clinical Endocrinology & Metabolism, 2014. 99(10): p. 3595-3606.

205

Mittendorf, E., et al., Improvement of sleep disturbance and neurocognitive function after parathyroidectomy in patients with primary hyperparathyroidism. Endocrine Practice, 2007. 13(4): p. 338-344.

206

Pashtan, I., et al., Primary hyperparathyroidism in adolescents: the same but different. Pediatric surgery international, 2013. 29(3): p. 275-279.

207

Paunovic, I., et al., Primary Hyperparathyroidism in Children and Young Adults:-A Single Institution Experience. Acta chirurgica Belgica, 2013. 113(1): p. 35-39.

208

Mack, L.A. and J.L. Pasieka, Asymptomatic primary hyperparathyroidism: a surgical perspective. The Surgical clinics of North America, 2004. 84(3): p. 803-816.

209

Almqvist, E.G., et al., Early parathyroidectomy increases bone mineral density in patients with mild primary hyperparathyroidism: a prospective and randomized study. Surgery, 2004. 136(6): p. 1281-1288.

210

Schillaci, G., et al., Large-artery stiffness: a reversible marker of cardiovascular risk in primary hyperparathyroidism. Atherosclerosis, 2011. 218(1): p. 96-101.

211

Silverberg, S.J., et al., Current Issues in the Presentation of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Fourth International Workshop. The Journal of Clinical Endocrinology & Metabolism, 2014. 99(10): p. 3580-3594.

212

Stewart, Z.A., et al., 25-hydroxyvitamin D deficiency is a risk factor for symptoms of postoperative hypocalcemia and secondary hyperparathyroidism after minimally invasive parathyroidectomy. Surgery, 2005. 138(6): p. 1018-1026.

213

Udelsman, R., Z. Lin, and P. Donovan, The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Annals of surgery, 2011. 253(3): p. 585-591.

214

Venkat, R., et al., Long-term outcome in patients with primary hyperparathyroidism who underwent minimally invasive parathyroidectomy. World journal of surgery, 2012. 36(1): p. 55-60.

215

Suliburk, J.W., et al., 1000 minimally invasive parathyroidectomies without intra‐operative parathyroid hormone measurement: lessons learned. ANZ journal of surgery, 2011. 81(5): p. 362-365.

216

Aspinall, S.R., S. Boase, and P. Malycha, Long-term symptom relief from primary hyperparathyroidism following minimally invasive parathyroidectomy. World journal of surgery, 2010. 34(9): p. 2223-2227.

217

Lombardi, C.P., et al., Video-assisted minimally invasive parathyroidectomy: benefits and long-term results. World journal of surgery, 2009. 33(11): p. 2266.

218

Wilhelm, S.M., et al., The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA Surgery, 2016. 151(10): p. 959-968.

219

McCoy, K.L., et al., The Small Abnormal Parathyroid Gland is Increasingly Common and Heralds Operative Complexity. World Journal of Surgery, 2014. 38(6): p. 1274-1281.

220

Miccoli, P., et al., Minimally invasive, video-assisted parathyroid surgery for primary hyperparathyroidism. Journal of endocrinological investigation, 1997. 20(7): p. 429-430.

221

Garimella, V., et al., Minimally invasive video-assisted parathyroidectomy is a safe procedure to treat primary hyperparathyroidism. the surgeon, 2012. 10(4): p. 202-205.

222

Allendorf, J., et al., 1112 consecutive bilateral neck explorations for primary hyperparathyroidism. World journal of surgery, 2007. 31(11): p. 2075-2080.

223

Abdulla, A.G., et al., Trends in the frequency and quality of parathyroid surgery: analysis of 17,082 cases over 10 years. Annals of surgery, 2015. 261(4): p. 746-750.

224

Lumachi, F., et al., Advantages of combined technetium-99msestamibi scintigraphy and high-resolution ultrasonography in parathyroid localization: comparative study in 91 patients with primary hyperparathyroidism. European journal of endocrinology, 2000. 143(6): p. 755-760.

225

Purcell, G.P., et al., Parathyroid localization with high-resolution ultrasound and technetium Tc 99m sestamibi. Archives of Surgery, 1999. 134(8): p. 824-830.

226

Casara, D., et al., 99mTc-MIBI radio-guided minimally invasive parathyroidectomy: experience with patients with normal thyroids and nodular goiters. Thyroid, 2002. 12(1): p. 53-61.

227

Irvin, G.L., V.D. Dembrow, and D.L. Prudhomme, Operative monitoring of parathyroid gland hyperfunction. The American journal of surgery, 1991. 162(4): p. 299-302.

228

Irvin III, G.L., D.M. Carneiro, and C.C. Solorzano, Progress in the operative management of sporadic primary hyperparathyroidism over 34 years. Annals of surgery, 2004. 239(5): p. 704.

229

Woodrum, D.T., et al., The influence of sample site on intraoperative PTH monitoring during parathyroidectomy. Surgery, 2004. 136(6): p. 1169-1175.

230

Кузнецов, Н., И. Ким, and С. Кузнецов, Интраоперационное определение паратгормона в стратегии хирургического лечения первичного гиперпаратиреоза. Эндокринная хирургия, 2011(2).

231

Barczynski, M., et al., Evaluation of Halle, Miami, Rome, and Vienna intraoperative iPTH assay criteria in guiding minimally invasive parathyroidectomy. Langenbeck’s archives of surgery, 2009. 394(5): p. 843-849.

232

Alesina, P.F., et al., Feasibility of video-assisted bilateral neck exploration for patients with primary hyperparathyroidism and failed or discordant localization studies. Langenbeck’s archives of surgery, 2013. 398(1): p. 107-111.

233

McGill, J., et al., How does the operative strategy for primary hyperparathyroidism impact the findings and cure rate? A comparison of 800 parathyroidectomies. Journal of the American College of Surgeons, 2008. 207(2): p. 246-249.

234

Järhult, J., et al., Long‐term results of surgery for lithium‐associated hyperparathyroidism. British Journal of Surgery, 2010. 97(11): p. 1680-1685.

235

Marti, J.L., et al., Surgical approach and outcomes in patients with lithium-associated hyperparathyroidism. Annals of surgical oncology, 2012. 19(11): p. 3465-3471.

236

Thakker, R.V., et al., Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1). The Journal of Clinical Endocrinology & Metabolism, 2012. 97(9): p. 2990-3011.

237

Sandelin, K., et al., Prognostic factors in parathyroid cancer: a review of 95 cases. World journal of surgery, 1992. 16(4): p. 724-731.

238

Schulte, K.-M. and N. Talat, Diagnosis and management of parathyroid cancer. Nature Reviews Endocrinology, 2012. 8(10): p. 612.

239

Hundahl, S.A., et al., Two hundred eighty‐six cases of parathyroid carcinoma treated in the US between 1985–1995: a National Cancer Data Base Report. Cancer, 1999. 86(3): p. 538-544.

240

Miura, D., et al., Does intraoperative quick parathyroid hormone assay improve the results of parathyroidectomy? World journal of surgery, 2002. 26(8): p. 926-930.

241

Libutti, S.K., et al., Kinetic analysis of the rapid intraoperative parathyroid hormone assay in patients during operation for hyperparathyroidism. Surgery, 1999. 126(6): p. 1145-1151.

242

Richards, M.L., et al., An optimal algorithm for intraoperative parathyroid hormone monitoring. Archives of Surgery, 2011. 146(3): p. 280-285.

243

Gawande, A.A., et al., Reassessment of parathyroid hormone monitoring during parathyroidectomy for primary hyperparathyroidism after 2 preoperative localization studies. Archives of Surgery, 2006. 141(4): p. 381-384.

244

Kald, B., et al., Risk assessment for severe postoperative hypocalcaemia after neck exploration for primary hyperparathyroidism. Scandinavian journal of surgery, 2005. 94(3): p. 216-220.

245

Mittendorf, E.A., J.I. Merlino, and C.R. McHenry, Post-Parathyroidectomy Hypocalcemia: Incidence, Risk Factors, and Management/DISCUSSION. The American surgeon, 2004. 70(2): p. 114.

246

Strickland, P.L. and J. Recabaren, Are preoperative serum calcium, parathyroid hormone, and adenoma weight predictive of postoperative hypocalcemia? The American surgeon, 2002. 68(12): p. 1080.

247

Bergenfelz, A., et al., Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial. Annals of surgery, 2002. 236(5): p. 543.

248

Roman, S.A., et al., The effects of serum calcium and parathyroid hormone changes on psychological and cognitive function in patients undergoing parathyroidectomy for primary hyperparathyroidism. Annals of surgery, 2011. 253(1): p. 131-137.

249

Sperlongano, P., et al., Postoperative hypocalcemia: assessment timing. International Journal of Surgery, 2014. 12: p. S95-S97.

250

Sinha, S. and D.K. Baskota, Comparison of corrected serum calcium changes following thyroid and non thyroid neck surgeries. Nepalese Journal of ENT Head and Neck Surgery, 2015. 6(1): p. 1-4.

251

Bergenfelz, A., et al., Conventional bilateral cervical exploration versus open minimally invasive parathyroidectomy under local anaesthesia for primary hyperparathyroidism. British Journal of Surgery: Incorporating European Journal of Surgery and Swiss Surgery, 2005. 92(2): p. 190-197.

252

Witteveen, J.E., et al., Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. Eur J Endocrinol, 2013. 168(3): p. R45-53.

253

Mitchell, D.M., et al., Long-term follow-up of patients with hypoparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 2012. 97(12): p. 4507-4514.

254

Puzziello, A., et al., Hypocalcemia following thyroid surgery: incidence and risk factors. A longitudinal multicenter study comprising 2,631 patients. Endocrine, 2014. 47(2): p. 537-542.

255

Khan, M., S. Waguespack, and M. Hu, Medical management of postsurgical hypoparathyroidism. Endocrine Practice, 2010. 17(Supplement 1): p. 18-25.

256

Yu, N., et al., The natural history of treated and untreated primary hyperparathyroidism: the parathyroid epidemiology and audit research study. QJM: An International Journal of Medicine, 2011. 104(6): p. 513-521.

257

Cassibba, S., et al., Silent renal stones in primary hyperparathyroidism: prevalence and clinical features. Endocrine Practice, 2014. 20(11): p. 1137-1142.

258

Majid, H., et al., IDENTIFYING PARATHYROID HORMONE DISORDERS AND THEIR PHENOTYPES THROUGH A BONE HEALTH SCREENING PANEL: IT’S NOT SIMPLE VITAMIN D DEFICIENCY! Endocrine Practice, 2016. 22(7): p. 814-821.

259

Ross, A.C., The 2011 report on dietary reference intakes for calcium and vitamin D. Public health nutrition, 2011. 14(5): p. 938-939.

260

Locker, F.G., S.J. Silverberg, and J.P. Bilezikian, Optimal dietary calcium intake in primary hyperparathyroidism. The American journal of medicine, 1997. 102(6): p. 543-550.

261

Jorde, R., et al., The effects of calcium supplementation to patients with primary hyperparathyroidism and a low calcium intake. European journal of nutrition, 2002. 41(6): p. 258-263.

262

Riss, P., et al., The influence of thiazide intake on calcium and parathyroid hormone levels in patients with primary hyperparathyroidism. Clinical endocrinology, 2016. 85(2): p. 196-201.

263

Tsvetov, G., et al., Thiazide treatment in primary hyperparathyroidism—a new indication for an old medication? The Journal of Clinical Endocrinology & Metabolism, 2016. 102(4): p. 1270-1276.

264

Nawrot, I., et al., Reoperations for persistent or recurrent primary hyperparathyroidism: results of a retrospective cohort study at a tertiary referral center. Medical science monitor: international medical journal of experimental and clinical research, 2014. 20: p. 1604.

265

Udelsman, R., Approach to the patient with persistent or recurrent primary hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 2011. 96(10): p. 2950-2958.

266

Akerstrom, G., Current controversy in parathyroid operation and reoperation. Parathyroid pathology, 1994: p. 23-41.

267

McDow, A.D. and R.S. Sippel, Should Symptoms Be Considered an Indication for Parathyroidectomy in Primary Hyperparathyroidism? Clinical Medicine Insights: Endocrinology and Diabetes, 2018. 11: p. 1179551418785135.

268

Marcocci, C., et al., Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 2014. 99(10): p. 3607-3618.

269

Sankaran, S., et al., Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis. The Journal of Clinical Endocrinology & Metabolism, 2010. 95(4): p. 1653-1662.

270

Khan, A., et al., Cinacalcet normalizes serum calcium in a doubleblind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery. Eur J Endocrinol, 2015. 172(5): p. 527-35.

271

Leere, J.S., et al., Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, doubleblind, placebo-controlled, phase 3 trial. The Lancet Diabetes & Endocrinology, 2020. 8(5): p. 407-417.

272

Palermo, A., R. Cesareo, E. Di Stasio, F. Vescini, G. Campagna, R. Cianni, V. Pasqualini, F. Romitelli, F. Grimaldi, S. Manfrini &. Osteoporos Int, 2015. 26: p. 1295-1302.

273

Drake, M.T., B.L. Clarke, and S. Khosla. Bisphosphonates: mechanism of action and role in clinical practice. in Mayo Clinic Proceedings. 2008. Elsevier.

274

Segula, D., et al., Long term outcome of bisphosphonate therapy in patients with primary hyperparathyroidism. International Journal of Clinical Medicine, 2014. 5(14): p. 829.

275

Yeh, M.W., et al., The relationship of parathyroidectomy and bisphosphonates with fracture risk in primary hyperparathyroidism: an observational study. Annals of internal medicine, 2016. 164(11): p. 715-723.

276

Vera, L., et al., Five-year longitudinal evaluation of mild primary hyperparathyroidism—medical treatment versus clinical observation. Endokrynologia Polska, 2014. 65(6): p. 456-463.

277

Rossini, M., et al., Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. Journal of Bone and Mineral Research, 2001. 16(1): p. 113-119.

278

Parker, C., et al., Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. The Journal of Clinical Endocrinology & Metabolism, 2002. 87(10): p. 4482-4489.

279

Chow, C., et al., Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 2003. 88(2): p. 581-587.

280

Khan, A.A., et al., Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology & Metabolism, 2004. 89(7): p. 3319-3325.

281

Khan, A., et al., Alendronate therapy in men with primary hyperparathyroidism. Endocrine Practice, 2009. 15(7): p. 705-713.

282

Grigorie, D. and A. Sucaliuc, A SINGLE-DOSE, OPEN-LABEL, PROSPECTIVE CLINICAL STUDY OF DENOSUMAB IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM. Acta Endocrinologica (1841-0987), 2014. 10(3).

283

Eller‐Vainicher, C., et al., Protective Effect of Denosumab on Bone in Older Women with Primary Hyperparathyroidism. Journal of the American Geriatrics Society, 2018. 66(3): p. 518-524.

284

Shalaby, T., et al., The Use of Denosumab in a Nonagenarian with Primary Hyperparathyroidism. European endocrinology, 2014. 10(2): p. 151.

285

Rozhinskaya, L.Y., et al., Denosumab treatment in patients with different courses of osteoporosis. Osteoporosis and Bone Diseases, 2017. 20(2): p. 58-62.

286

Tong, C., et al., Use of denosumab in parathyroid carcinoma with refractory hypercalcemia. QJM, 2015. 108(1): p. 49-50.

287

Fountas, A., et al., The emerging role of denosumab in the longterm management of parathyroid carcinoma-related refractory hypercalcemia. Endocrine Practice, 2015. 21(5): p. 468-473.

288

Mandema, J.W., et al., Time Course of Bone Mineral Density Changes With Denosumab Compared With Other Drugs in Postmenopausal Osteoporosis: A Dose-Response–Based Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism, 2014. 99(10): p. 3746-3755.

289

Peacock, M., et al., Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. The Journal of Clinical Endocrinology & Metabolism, 2009. 94(12): p. 4860-4867.

290

Faggiano, A., et al., Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. Endocrine, 2011. 39(3): p. 283-287.

291

Sajid-Crockett, S., F.R. Singer, and J.M. Hershman, Cinacalcet for the treatment of primary hyperparathyroidism. Metabolism, 2008. 57(4): p. 517-521.

292

Iglesias, P., et al., Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy. The American journal of the medical sciences, 2008. 335(2): p. 111-114.

293

Martín, A.A., et al., Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery. Endocrinología y Nutrición (English Edition), 2011. 58(1): p. 24-31.

294

Cetani, F., et al., Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling. Journal of endocrinological investigation, 2012. 35(7): p. 655-660.

295

Filopanti, M., et al., MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly. European journal of endocrinology, 2012. 167(2): p. 157-164.

296

Luque-Fernández, I., A. García-Martín, and A. Luque-Pazos, Experience with cinacalcet in primary hyperparathyroidism: results after 1 year of treatment. Therapeutic advances in endocrinology and metabolism, 2013. 4(3): p. 77-81.

297

Saponaro, F., et al., Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group. Clinical endocrinology, 2013. 79(1): p. 20-26.

298

Shah, V.N., et al., Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25 (OH) D, calcium and PTH levels: a meta‐analysis and review of literature. Clinical endocrinology, 2014. 80(6): p. 797-803.

299

Norenstedt, S., et al., Vitamin D Supplementation After Parathyroidectomy: Effect on Bone Mineral Density—A Randomized Double‐Blind Study. Journal of Bone and Mineral Research, 2014. 29(4): p. 960-967.

300

Stein, E.M., et al., Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism. Bone, 2011. 48(3): p. 557-561.

301

Holick, M.F., Resurrection of vitamin D deficiency and rickets. The Journal of clinical investigation, 2006. 116(8): p. 2062-2072.

302

Bischoff-Ferrari, H.A., et al., Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes–. The American journal of clinical nutrition, 2006. 84(1): p. 18-28.

303

Rolighed, L., et al., Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J Clin Endocrinol Metab, 2014. 99(3): p. 1072-1080.

304

Westerdahl, J., et al., Risk factors for postoperative hypocalcemia after surgery for primary hyperparathyroidism. Archives of Surgery, 2000. 135(2): p. 142-147.

305

Carty, S.E., et al., Elevated serum parathormone level after “concise parathyroidectomy” for primary sporadic hyperparathyroidism. Surgery, 2002. 132(6): p. 1086-1093.

306

Carneiro, D.M. and G.L. Irvin III, Late parathyroid function after successful parathyroidectomy guided by intraoperative hormone assay (QPTH) compared with the standard bilateral neck exploration. Surgery, 2000. 128(6): p. 925-929.

307

Beyer, T.D., et al., Oral vitamin D supplementation reduces the incidence of eucalcemic PTH elevation after surgery for primary hyperparathyroidism. Surgery, 2007. 141(6): p. 777-783.

308

Kantorovich, V., et al., Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 2000. 85(10): p. 3541-3543.

309

Ahmad, S., G. Kuraganti, and D. Steenkamp, Hypercalcemic crisis: a clinical review. The American journal of medicine, 2015. 128(3): p. 239-245.

310

Schweitzer, V.G., et al., Management of severe hypercalcemia caused by primary hyperparathyroidism. Archives of surgery (Chicago, Ill.: 1960), 1978. 113(4): p. 373-381.

311

Cannon, J., J.I. Lew, and C.C. Solórzano, Parathyroidectomy for hypercalcemic crisis: 40 years’ experience and long-term outcomes. Surgery, 2010. 148(4): p. 807-813.

312

Phitayakorn, R. and C.R. McHenry, Hyperparathyroid crisis: use of bisphosphonates as a bridge to parathyroidectomy. Journal of the American College of Surgeons, 2008. 206(6): p. 1106-1115.

313

Starker, L.F., et al., Clinical and histopathological characteristics of hyperparathyroidism-induced hypercalcemic crisis. World journal of surgery, 2011. 35(2): p. 331-335.

314

Beck, W., J.I. Lew, and C.C. Solórzano, Hypercalcemic crisis in the era of targeted parathyroidectomy. Journal of Surgical Research, 2011. 171(2): p. 404-408.

315

Bilezikian, J.P., Management of acute hypercalcemia. New England Journal of Medicine, 1992. 326(18): p. 1196-1203.

316

Gurrado, A., et al., Hypercalcaemic crisis due to primary hyperparathyroidism—a systematic literature review and case report. Endokrynologia Polska, 2012. 63(6): p. 494-502.

317

NAKAOKA, D., et al., Evaluation of changes in bone density and biochemical parameters after parathyroidectomy in primary hyperparathyroidism. Endocrine journal, 2000. 47(3): p. 231-237.

318

Nordenström, E., J. Westerdahl, and A. Bergenfelz, Recovery of bone mineral density in 126 patients after surgery for primary hyperparathyroidism. World journal of surgery, 2004. 28(5): p. 502-507.

319

Brandi, M.L., et al., Consensus: guidelines for diagnosis and therapy of MEN type 1 and type 2. The Journal of Clinical Endocrinology & Metabolism, 2001. 86(12): p. 5658-5671.

320

Lassen, T., et al., Primary hyperparathyroidism in young people. When should we perform genetic testing for multiple endocrine neoplasia 1 (MEN-1)? The Journal of Clinical Endocrinology & Metabolism, 2014. 99(11): p. 3983-3987.

321

Giusti, F., et al., Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine, 2017. 58(2): p. 349-359.

322

Sakurai, A., et al., Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of a multicentre database. Clinical endocrinology, 2012. 76(4): p. 533-539.

323

Manoharan, J., et al., Is routine screening of young asymptomatic MEN1 patients necessary? World journal of surgery, 2017. 41(8): p. 2026-2032.

324

Goudet, P., et al., Risk factors and causes of death in MEN1 disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) cohort study among 758 patients. World journal of surgery, 2010. 34(2): p. 249-255.

325

Trouillas, J., et al., Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. The American journal of surgical pathology, 2008. 32(4): p. 534-543.

326

Gibril, F., et al., Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. The Journal of Clinical Endocrinology & Metabolism, 2001. 86(11): p. 5282-5293.

327

Ito, T., et al., Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine, 2013. 92(3): p. 135.

328

Eller‐Vainicher, C., et al., Sporadic and MEN1‐related primary hyperparathyroidism: differences in clinical expression and severity. Journal of Bone and Mineral Research, 2009. 24(8): p. 1404-1410.

329

Hosking, S.W., et al., Surgery for parathyroid adenoma and hyperplasia: relationship of histology to outcome. Head & neck, 1993. 15(1): p. 24-28.

330

Machens, A., et al., Age‐related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clinical endocrinology, 2007. 67(4): p. 613-622.

331

Schaaf, L., et al., Developing effective screening strategies in multiple endocrine neoplasia type 1 (MEN 1) on the basis of clinical and sequencing data of German patients with MEN 1. Experimental and clinical endocrinology & diabetes, 2007. 115(08): p. 509-517.

332

Carling, T. and R. Udelsman, Parathyroid surgery in familial hyperparathyroid disorders. Journal of internal medicine, 2005. 257(1): p. 27-37.

333

Ростомян, Л.Г., Синдром множественных эндокринных неоплазий 1 типа: распространенность среди пациентов с первичным гиперпаратиреозом, клинические и молекулярно-генетические характеристики. Дис.... кандидат медицинских наук. М, 2011.

334

Goudet, P., et al., MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d’étude des Tumeurs Endocrines. The Journal of Clinical Endocrinology & Metabolism, 2015. 100(4): p. 1568-1577.

335

Triponez, F., et al., Long-term follow-up of MEN1 patients who do not have initial surgery for small≤ 2 cm nonfunctioning pancreatic neuroendocrine tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne & Groupe d’Etude des Tumeurs Endocrines. Annals of surgery, 2018. 268(1): p. 158.

336

de Laat, J.M., et al., Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients. The Journal of Clinical Endocrinology & Metabolism, 2013. 98(10): p. 4143-4151.

337

Conemans, E.B., et al., Prognostic factors for survival of MEN1 patients with duodenopancreatic tumors metastatic to the liver: results from the DMSG. Endocrine Practice, 2017. 23(6): p. 641-648.

338

Tomassetti, P., et al., Endocrine pancreatic tumors: factors correlated with survival. Annals of Oncology, 2005. 16(11): p. 1806-1810.

339

Skandarajah, A., et al., Should routine analysis of the MEN1 gene be performed in all patients with primary hyperparathyroidism under 40 years of age? World journal of surgery, 2010. 34(6): p. 1294-1298.

340

Starker, L.F., et al., Frequent germ-line mutations of the MEN1, CASR, and HRPT2/CDC73 genes in young patients with clinically nonfamilial primary hyperparathyroidism. Hormones and Cancer, 2012. 3(1-2): p. 44-51.

341

Wit, D., V. Der Luijt, and P. van Amstel, Criteria for mutation analysis in MEN 1‐suspected patients: MEN 1 case‐finding. European journal of clinical investigation, 2000. 30(6): p. 487-492.

342

Cardinal, J., et al., A report of a national mutation testing service for the MEN1 gene: clinical presentations and implications for mutation testing. Journal of medical genetics, 2005. 42(1): p. 69-74.

343

Langer, P., et al., Prevalence of multiple endocrine neoplasia type 1 in young patients with apparently sporadic primary hyperparathyroidism or pancreaticoduodenal endocrine tumours. British journal of surgery, 2003. 90(12): p. 1599-1603.

344

Мамедова, Е.О., et al., Молекулярно-генетические особенности первичного гиперпаратиреоза у пациентов молодого возраста. Проблемы эндокринологии, 2016. 62(2).

345

Elaraj, D.M., et al., Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery, 2003. 134(6): p. 858-864.

346

Lairmore, T.C., et al., A randomized, prospective trial of operative treatments for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery, 2014. 156(6): p. 1326-1335.

347

Pieterman, C.R., et al., Primary hyperparathyroidism in MEN1 patients: a cohort study with longterm follow-up on preferred surgical procedure and the relation with genotype. Annals of surgery, 2012. 255(6): p. 1171-1178.

348

Lambert, L.A., et al., Surgical treatment of hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Archives of Surgery, 2005. 140(4): p. 374-382.

349

Salmeron, M.D.B., et al., Causes and treatment of recurrent hyperparathyroidism after subtotal parathyroidectomy in the presence of multiple endocrine neoplasia 1. World journal of surgery, 2010. 34(6): p. 1325-1331.

350

Lairmore, T.C., et al., Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1). Annals of surgery, 2004. 239(5): p. 637.

351

Giusti, F., F. Tonelli, and M.L. Brandi, Primary hyperparathyroidism in multiple endocrine neoplasia type 1: when to perform surgery? Clinics, 2012. 67: p. 141-144.

352

Powell, A.C., et al., The utility of routine transcervical thymectomy for multiple endocrine neoplasia 1-related hyperparathyroidism. Surgery, 2008. 144(6): p. 878-884.

353

Ferolla, P., et al., Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series. The Journal of Clinical Endocrinology & Metabolism, 2005. 90(5): p. 2603-2609.

354

Burgess, J.R., N. Giles, and J.J. Shepherd, Malignant thymic carcinoid is not prevented by transcervical thymectomy in multiple endocrine neoplasia type 1. Clinical endocrinology, 2001. 55(5): p. 689-693.

355

Gatta-Cherifi, B., et al., Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d’etude des Tumeurs Endocrines database. European journal of endocrinology, 2012. 166(2): p. 269-279.

356

Yip, L., et al., Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Archives of Surgery, 2003. 138(4): p. 409-416.

357

Voss, R.K., et al., Medullary thyroid carcinoma in MEN2A: ATA moderate-or high-risk RET mutations do not predict disease aggressiveness. The Journal of Clinical Endocrinology & Metabolism, 2017. 102(8): p. 2807-2813.

358

Lairmore, T.C., et al., Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes. Annals of surgery, 1993. 217(6): p. 595.

359

Raue, F., et al., Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. Journal of internal medicine, 1995. 238(4): p. 369-373.

360

Scholten, A., et al., Evolution of surgical treatment of primary hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. Endocrine practice, 2010. 17(1): p. 7-15.

361

Magalhães, P.K.R., et al., Primary hyperparathyroidism as the first clinical manifestation of multiple endocrine neoplasia type 2A in a 5-year-old child. Thyroid, 2011. 21(5): p. 547-550.

362

Keiser, H.R., et al., Sipple’s syndrome: medullary thyroid carcinoma, pheochromocytoma, and parathyroid disease: studies in a large family. Annals of internal medicine, 1973. 78(4): p. 561-579.

363

Kraimps, J.L., et al., Hyperparathyroidism in multiple endocrine neoplasia syndrome. Surgery, 1992. 112(6): p. 1080-1088.

364

Herfarth, K.K.-F., et al., Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. Surgery, 1996. 120(6): p. 966-974.

365

Kraimps, J.-L., et al., Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. World journal of surgery, 1996. 20(7): p. 808-813.

366

Iacobone, M., et al., Hereditary hyperparathyroidism—a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbeck’s archives of surgery, 2015. 400(8): p. 867-886.

367

Iacobone, M., et al., Hyperparathyroidism–jaw tumor syndrome: a report of three large kindred. Langenbeck’s archives of surgery, 2009. 394(5): p. 817-825.

368

Jackson, C.E., et al., Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery, 1990. 108(6): p. 1006-12; discussion 1012-3.

369

van der Tuin, K., et al., CDC73-related disorders: clinical manifestations and case detection in primary hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 2017. 102(12): p. 4534-4540.

370

Pichardo-Lowden, A., et al., Familial hyperparathyroidism due to a germline mutation of the CDC73 gene: implications for management and age-appropriate testing of relatives at risk. Endocrine Practice, 2011. 17(4): p. 602-609.

371

Harman, C.R., et al., Sporadic primary hyperparathyroidism in young patients: a separate disease entity? Archives of surgery, 1999. 134(6): p. 651-656.

372

Lee, M. and N.S. Pellegata, Multiple endocrine neoplasia type 4, in Endocrine Tumor Syndromes and Their Genetics. 2013, Karger Publishers. p. 63-78.

373

Giusti, F., et al., Hereditary hyperparathyroidism syndromes. Journal of Clinical Densitometry, 2013. 16(1): p. 69-74.

374

Simonds, W.F., et al., Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine, 2002. 81(1): p. 1-26.

375

Lee, P.K., et al., Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer, 2007. 109(9): p. 1736-1741.

376

Cetani, F., E. Pardi, and C. Marcocci, Parathyroid carcinoma: a clinical and genetic perspective. Minerva endocrinologica, 2018. 43(2): p. 144-155.

377

Ryhänen, E.M., et al., A nationwide study on parathyroid carcinoma. Acta Oncologica, 2017. 56(7): p. 991-1003.

378

Мокрышева, Н.Г., Ю.А. Крупинова, и С.С. Мирная, Клинические и лабораторно-инструментальные возможности предоперационной диагностики рака околощитовидных желез. Эндокринная хирургия, 2017. 11(3).

379

Talat, N. and K.-M. Schulte, Clinical presentation, staging and longterm evolution of parathyroid cancer. Annals of surgical oncology, 2010. 17(8): p. 2156-2174.

380

Erovic, B.M., et al., Parathyroid cancer: outcome analysis of 16 patients treated at the Princess Margaret Hospital. Head & neck, 2013. 35(1): p. 35-39.

381

Shane, E., Parathyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism, 2001. 86(2): p. 485-493.

382

Busaidy, N.L., et al., Parathyroid carcinoma: a 22‐year experience. Head & Neck: Journal for the Sciences and Specialties of the Head and Neck, 2004. 26(8): p. 716-726.

383

Wang, L., et al., Non-functional parathyroid carcinoma: a case report and review of the literature. Cancer biology & therapy, 2015. 16(11): p. 1569-1576.

384

Montenegro, F.L.d.M., et al., Clinical suspicion and parathyroid carcinoma management. Sao Paulo Medical Journal, 2006. 124(1): p. 42-44.

385

Villar-del-Moral, J., et al., Prognostic factors and staging systems in parathyroid cancer: a multicenter cohort study. Surgery, 2014. 156(5): p. 1132-1144.

386

Schulte, K.-M., et al., Oncologic resection achieving r0 margins improves disease-free survival in parathyroid cancer. Annals of surgical oncology, 2014. 21(6): p. 1891-1897.

387

Hsu, K.-T., et al., Is central lymph node dissection necessary for parathyroid carcinoma? Surgery, 2014. 156(6): p. 1336-1341.

388

Erickson, L.A., et al., Overview of the 2022 WHO Classification of Parathyroid Tumors. Endocrine Pathology, 2022. 33(1): p. 64-89.

389

DeLellis, R.A., Pathology and genetics of tumours of endocrine organs. Vol. 8. 2004: IARC.

390

Lloyd, R., OR, Klöppel G, Rosai J. WHO Classification of Tumours of Endocrine Organs. 4th edition. WHO, Geneva, 2017.

391

Landry, C., et al., Parathyroid. AJCC Cancer Staging Manual, 2017: p. 903-910.

392

Мамедова, Е., и др., Мутации в гене CDC73 у молодых пациенток с первичным гиперпаратиреозом (описание двух клинических случаев). Терапевтический архив (архив до 2018 г.), 2016. 88(10): p. 57-62.

393

Newey, P.J., et al., Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism‐jaw tumor syndrome (HPT‐JT) and parathyroid tumors. Human mutation, 2010. 31(3): p. 295-307.

394

Pandya, C., et al., Genomic profiling reveals mutational landscape in parathyroid carcinomas. JCI insight, 2017. 2(6).

395

Shattuck, T.M., et al., Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. New England Journal of Medicine, 2003. 349(18): p. 1722-1729.

396

Carpten, J., et al., HRPT2, encoding parafibromin, is mutated in hyperparathyroidism–jaw tumor syndrome. Nature genetics, 2002. 32(4): p. 676.

397

Demir, H., et al., FDG PET/CT findings in primary hyperparathyroidism mimicking multiple bone metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2008. 35(3): p. 686-686.

398

Мокрышева, Н., и др., Позитронная эмиссионная томография совмещенная с компьютерной томографией с 18 F-фторхолином в топической диагностике опухолей околощитовидных желез и вторичных изменений костной ткани при гиперпаратиреоидной остеодистрофии: два клинических наблюдения. Problemy Endokrinologii, 2018. 64(5).

399

Penhoat, M.G., et al., Contribution of 18-FDG PET/CT to brown tumor detection in a patient with primary hyperparathyroidism. Joint Bone Spine, 2017. 84(2): p. 209-212.

400

Calandra, D., et al., Parathyroid carcinoma: biochemical and pathologic response to DTIC. Surgery, 1984. 96(6): p. 1132.

401

Bukowski, R.M., et al., Successful combination chemotherapy for metastatic parathyroid carcinoma. Archives of Internal Medicine, 1984. 144(2): p. 399-400.

402

Munson, N.D., et al., Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer, 2003. 98(11): p. 2378-2384.

403

Wynne, A.G., et al., Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine, 1992. 71(4): p. 197-205.

404

Sanden, A.K. and P. Vestergaard, Kontrol af serumcalcium med cinacalcet ved parathyroideacancer. Ugeskrift for Laeger, 2009. 171(41): p. 3004-6.

405

Çalapkulu, M., et al., Control of Refractory Hypercalcemia with Denosumab in a Case of Metastatic Parathyroid Carcinoma. Journal of the College of Physicians and Surgeons--Pakistan: JCPSP, 2020. 30(7): p. 757-759.

406

Fountas, A., S. Tigas, and A. Tsatsoulis, Denosumab is a long-term option for the management of parathyroid carcinoma-related refractory hypercalcemia. QJM: An International Journal of Medicine, 2017. 110(1): p. 53-54.

407

Takeuchi, Y., et al., Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism. Journal of bone and mineral metabolism, 2017. 35(6): p. 616-622.

408

Silverberg, S.J., et al., Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism, 2007. 92(10): p. 3803-3808.

409

Pramanik, S., et al., Parathyroid carcinoma and persistent hypercalcemia: A case report and review of therapeutic options. Saudi journal of medicine & medical sciences, 2018. 6(2): p. 115.

410

Thosani, S. and M.I. Hu, Denosumab: a new agent in the management of hypercalcemia of malignancy. Future Oncology, 2015. 11(21): p. 2865-2871.

411

Sun, L. and S. Yu, Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis. American journal of clinical oncology, 2013. 36(4): p. 399-403.

412

Chen, F. and F. Pu, Safety of Denosumab Versus Zoledronic Acid in Patients with Bone Metastases: A Meta-Analysis of Randomized Controlled Trials. Oncol Res Treat, 2016. 39(7-8): p. 453-9.

413

Rozhinskaya, L., et al., Diagnosis and treatment challenges of parathyroid carcinoma in a 27-year-old woman with multiple lung metastases. Endocrinol Diabetes Metab Case Rep, 2017. 2017.

414

Alharbi, N., et al., Intrathyroidal Parathyroid Carcinoma: An Atypical Thyroid Lesion. Front Endocrinol (Lausanne), 2018. 9: p. 641.

415

Mokrysheva, N., A. Lipatenkova, and N. Taller, Primary hyperparathyroidism and pregnancy.

416

Norman, J., D. Politz, and L. Politz, Hyperparathyroidism during pregnancy and the effect of rising calcium on pregnancy loss: a call for earlier intervention. Clinical endocrinology, 2009. 71(1): p. 104-109.

417

Schnatz, P.F. and S.L. Curry, Primary hyperparathyroidism in pregnancy: evidence-based management. Obstetrical & gynecological survey, 2002. 57(6): p. 365-376.

418

Hirsch, D., et al., Pregnancy outcomes in women with primary hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 2015. 100(5): p. 2115-2122.

419

Cassir, G., C. Sermer, and A.K. Malinowski, Impact of Perinatal Primary Hyperparathyroidism on Maternal and Fetal and Neonatal Outcomes: Retrospective Case Series. Journal of Obstetrics and Gynaecology Canada, 2020.

420

McMullen, T.P., et al., Hyperparathyroidism in pregnancy: options for localization and surgical therapy. World journal of surgery, 2010. 34(8): p. 1811-1816.

421

Vitetta, G.M., et al., Role of ultrasonography in the management of patients with primary hyperparathyroidism: retrospective comparison with technetium-99m sestamibi scintigraphy. Journal of ultrasound, 2014. 17(1): p. 1-12.

422

Shaw, P., et al., Radiation exposure and pregnancy. 2011, Elsevier.

423

Diaz-Soto, G., et al., Primary hyperparathyroidism in pregnancy. Endocrine, 2013. 44(3): p. 591-597.

424

Malekar-Raikar, S. and B. Sinnott, Primary hyperparathyroidism in pregnancy—a rare cause of life-threatening hypercalcemia: case report and literature review. Case reports in endocrinology, 2011. 2011.

425

Ip, P., Neonatal convulsion revealing maternal hyperparathyroidism: an unusual case of late neonatal hypoparathyroidism. Archives of gynecology and obstetrics, 2003. 268(3): p. 227-229.

426

SHANGOLD, M.M., et al., Hyperparathyroidism and pregnancy: a review. Obstetrical & gynecological survey, 1982. 37(4): p. 217-228.

427

Kelly, T.R., Primary hyperparathyroidism during pregnancy. Surgery, 1991. 110(6): p. 1028-1034.

428

Kristoffersson, A., et al., Primary hyperparathyroidism in pregnancy. Surgery, 1985. 97(3): p. 326-330.

429

Walker, A., J.J. Fraile, and J.G. Hubbard, “Parathyroidectomy in pregnancy”—a single centre experience with review of evidence and proposal for treatment algorithim. Gland surgery, 2014. 3(3): p. 158.

430

Hu, Y., et al., Clinical presentation, management, and outcomes of primary hyperparathyroidism during pregnancy. International journal of endocrinology, 2017. 2017.

431

McCarthy, A., et al., Management of primary hyperparathyroidism in pregnancy: a case series. Endocrinology, diabetes & metabolism case reports, 2019. 2019(1).

432

Schnatz, P.F. and S. Thaxton, Parathyroidectomy in the third trimester of pregnancy. Obstetrical & gynecological survey, 2005. 60(10): p. 672-682.

433

Trebb, C., et al., Concurrent parathyroidectomy and caesarean section in the third trimester. Journal of Obstetrics and Gynaecology Canada, 2014. 36(6): p. 502-505.

434

Krysiak, R., M. Wilk, and B. Okopien, Recurrent pancreatitis induced by hyperparathyroidism in pregnancy. Archives of gynecology and obstetrics, 2011. 284(3): p. 531-534.

435

Levy, S., et al., Pregnancy outcome following in utero exposure to bisphosphonates. Bone, 2009. 44(3): p. 428-430.

436

Vera, L., et al., Primary hyperparathyroidism in pregnancy treated with cinacalcet: a case report and review of the literature. Journal of medical case reports, 2016. 10(1): p. 361.

437

Horjus, C., et al., Cinacalcet for hyperparathyroidism in pregnancy and puerperium. Journal of Pediatric Endocrinology and Metabolism, 2009. 22(8): p. 741-750.

438

Nadarasa, K., et al., The use of cinacalcet in pregnancy to treat a complex case of parathyroid carcinoma. Endocrinology, diabetes & metabolism case reports, 2014. 2014(1).

439

Carroll, R. and G. Matfin, Endocrine and metabolic emergencies: hypercalcaemia. Therapeutic advances in endocrinology and metabolism, 2010. 1(5): p. 225-234.

440

Eremkina, A., et al., Denosumab for management of severe hypercalcemia in primary hyperparathyroidism. Endocrine Connections, 2020. 9(10): p. 1019-1027.

441

Pekkolay, Z., et al., Preoperative Parenteral Ibandronate for Treating Severe Hypercalcemia Associated with Primary Hyperparathyroidism: An Effective and Cheap Drug. Turkish Journal of Endocrinology and Metabolism, 2018. 22(2): p. 39.

442

Oueslati, I., et al., Management of severe hypercalcemia secondary to primary hyperparathyroidism: The efficacy of saline hydration, furosemide, and zoledronic acid. Endocrinology, diabetes & metabolism case reports, 2022.

443

Alhefdhi, A., H. Mazeh, and H. Chen, Role of postoperative vitamin D and/or calcium routine supplementation in preventing hypocalcemia after thyroidectomy: a systematic review and meta-analysis. The Oncologist, 2013. 18(5): p. 533.

The authors declare that there are no conflicts of interest present.